OBJECTIVE To prepare 5-fluorouracil(5-Fu) loaded acicular implants and to investigate the in vitro 5-Fu release behaviors.METHODS The 5-Fu loaded implants were fabricated by hot-melting extrusion method,using PCL as matrix,PEG or gelatin as additive.X-ray diffraction(XRD) and scanning electron microscopy(SEM) were used to character the crystallinity and morphology of implants respectively.The influences of drug loading(12.5%,25%,50%),types of additives(PEG and gelatin),PEG or gelatin content(5%,10%,25%)on drug release behaviors were investigated.RESULTS The obtained implants were with smooth surface.5-Fu was dispersed uniformly in implants.Crystalline of 5-Fu,PCL and PEG in implants were observed.The higher drug loading,the faster drug release.The addition of PEG or gelatin accelerated drug release.CONCLUSION The fabrication process of implants was easy and feasible,drug release behaviors could be adjusted by changing drug loading,types of additives and additive content.Acicular implants could be potential for drug delivery within tumor.
YNG Hn;CHENG Ling;GUO Sheng-rong.
Study on Acicular Poly(ε-Caprolactone) Implants Containing 5-Fluorouracil [J]. Chinese Pharmaceutical Journal, 2009, 44(08): 602-606
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] JEAN L G. 5-Fluorouracil： forty-plus and still ticking. A review of its preclinical and clinical development[J]. Invest New Drugs，2000，18（4）：299-313.
[2] ROBERTO L，ROSA O，CéSAR T，et al. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(D，L-lactide) and poly(D，L-lactide-co-glycolide) polymers [J]. Int J Pharm，2007，338（1-2）：180-190.
[3] LU B. New Techniques and New Dosage Froms of Drugs（药物新剂型与新技术）[M]. Beijing：People′s Medicine Publishing House，1998：503-515.
[4] BREM H，EWEND M G，PIANTADOSI S，et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas： phase I trial[J]. J Neurooncol，1995，26(2)：111-123.
[5] SINHA V R，BANSAL K，KAUSHIK R，et al. Poly-ε-caprolactone microspheres and nanospheres：an overview [J]. Int J Pharm，2004，278（1）：1-23.
[6] ROHNER D，HUTMACHER D W，SEE P，et al. Individually CAD-CAM technique designed，bioresorbable 3-dimensional polycaprolactone framework for experimental reconstruction of craniofacial defects in the pig[J]. Mund Kiefer Gesichtschir，2002，6(3)：162-167.
[7] SANDRA H，GERHARD W，SILKE M，et al. Mechanisms controlling protein release from lipidic implants：Effects of PEG addition [J]. J Controlled Release，2007，118（2）：161-168.
[8] MALLADI S V，RAMESH B，BOYA V K N，et al. Encapsulation efficiency and controlled release characteristics of crosslinked polyacrylamide particles[J]. Int J Pharm，2006，320（1-2）：131-136.
[9] GUO Q H，GUO S R，WANG Z M. Estimation of 5-fluorouracil-loaded ethylene-vinyl acetate stent coating based on percolation thresholds [J]. Int J Pharm，2007，333（1-2）：95-102.
[10] WANG Y W，HSIN-I CHANG，DAVID F WERTHEIM，et al. Characterisation of the macroporosity of polycaprolactone-based biocomposites and release kinetics for drug delivery [J]. Biomaterials，2007，28（31）：4619-4627.
